

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
William Wold *et al.*

Serial No.: 10/810,063

Filed: March 26, 2004


For: ADENOVIRUS REPLICATION-
COMPETENT VECTORS EXPRESSING
TRAIL

Group Art Unit: 1635

Examiner: Whiteman, Brian A.

Atty. Dkt. No.: INGN:106US

Confirmation No.: 8527

CERTIFICATE OF ELECTRONIC TRANSMISSION	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
May 25, 2007	 Monica A. De La Paz
Date	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:106US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Monica A. De La Paz
Reg. No. 54,662
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 25, 2007

Form PTO-1449 (modified)		Atty. Docket No.: INGN:106US	Serial No.: 10/810,063
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: William Wold <i>et al.</i>	
		Filing Date: March 26, 2004	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C52	Carlin <i>et al.</i> , "Epidermal growth factor receptor is down-regulated by a 10,400 MW protein encoded by the E3 region of adenovirus," <i>Cell</i> , 57:135-144, 1989.
	C53	Chiou and White, "Inhibition of ICE-like Proteases Inhibits Apoptosis and Increases Virus Production during Adenovirus Infection," <i>Virology</i> , 244:108-118, 1998.
	C54	Dimitrov <i>et al.</i> , "Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes," <i>J. Virol.</i> , 71:2830-2837, 1997.
	C55	Gooding <i>et al.</i> , "A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor," <i>Cell</i> , 53:341-346, 1988.
	C56	Gooding <i>et al.</i> , "The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor," <i>J. Virol.</i> , 65:4114-4123, 1991.
	C57	Gooding <i>et al.</i> , "The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis," <i>J. Immunol.</i> , 145:3080-3086, 1990.
	C58	Habib <i>et al.</i> , "Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc)," <i>Cancer Gene Ther.</i> , 9:651-654, 2002.
	C59	Horton <i>et al.</i> , "A protein serologically and functionally related to the group C E3 14,700-kilodalton protein is found in multiple adenovirus serotypes," <i>J. Virol.</i> , 64:1250-1255, 1990.

25777578.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:106US	Serial No.: 10/810,063
List of Patents and Publications for Applicant's		Applicant: William Wold et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: March 26, 2004	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C60	Johnstone <i>et al.</i> , "Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival," <i>Mol. Cell Biol.</i> , 21:1672-1681, 2001.
	C61	Kladney <i>et al.</i> , "Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain," <i>Virology</i> , 301:236-246, 2002.
	C62	Krajcsi <i>et al.</i> , "The adenovirus E3 14.5-kilodalton protein, which is required for down-regulation of the epidermal growth factor receptor and prevention of tumor necrosis factor cytolysis, is an integral membrane protein oriented with its C terminus in the cytoplasm," <i>J. Virol.</i> , 66:1665-1673, 1992.
	C63	Krajcsi <i>et al.</i> , "The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid," <i>J. Virol.</i> , 70:4904-4913, 1996.
	C64	Krajcsi <i>et al.</i> , "The E3-10.4K protein of adenovirus is an integral membrane protein that is partially cleaved between Ala22 and Ala23 and has a Ccyt orientation," <i>Virology</i> , 187:131-144, 1992.
	C65	Krajcsi <i>et al.</i> , "The E3-14.5K integral membrane protein of adenovirus that is required for down-regulation of the EGF receptor and for prevention of TNF cytolysis is O-glycosylated but not N-glycosylated," <i>Virology</i> , 188:570-579, 1992.
	C66	Lichtenstein <i>et al.</i> , "Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis," <i>J. Virol.</i> , 76:11329-11342, 2002.
	C67	Rawle <i>et al.</i> , "Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K," <i>J. Immunol.</i> , 143:2031-2037, 1989.
	C68	Scaria <i>et al.</i> , "The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes the nuclear membrane," <i>Virology</i> , 191:743-753, 1992.
	C69	Stewart <i>et al.</i> , "The adenovirus E3 10.4K and 14.5K proteins, which function to prevent cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane," <i>J. Virol.</i> , 69:172-181, 1995.
	C70	Tollefson and Wold, "Identification and gene mapping of a 14,700-molecular-weight protein encoded by region E3 of group C adenoviruses," <i>J. Virol.</i> , 62:33-39, 1988.

25777578.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:106US	Serial No.: 10/810,063
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: William Wold <i>et al.</i>	
		Filing Date: March 26, 2004	Group: 1635
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C71	Tollefson <i>et al.</i> , "A 10,400-molecular-weight membrane protein is coded by region E3 of adenovirus," <i>J. Virol.</i> , 64:794-801, 1990.
	C72	Tollefson <i>et al.</i> , "A 14,500 MW protein is coded by region E3 of group C human adenoviruses," <i>Virology</i> , 175:19-29, 1990.
	C73	Tollefson <i>et al.</i> , "Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells," <i>Nature</i> , 392:726-730, 1998.
	C74	Tollefson <i>et al.</i> , "Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins," <i>J. Virol.</i> , 75:8875-8887, 2001.
	C75	Tollefson <i>et al.</i> , "The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus form a complex and function together to down-regulate the epidermal growth factor receptor," <i>J. Virol.</i> , 65:3095-3105, 1991.
	C76	Wilson-Rawls <i>et al.</i> , "A 6700 MW membrane protein is encoded by region E3 of adenovirus type 2," <i>Virology</i> , 178:204-212, 1990.
	C77	Wold <i>et al.</i> , "E3 transcription unit of adenovirus," <i>Curr. Top. Microbiol. Immunol.</i> , 199:237-274, 1995.

25777578.1

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	